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BACKGROUND
Hepatitis C virus (HCV) and Dengue virus (DENV) are both from the family of Flaviviridae
and have many characteristics in common. Although there are many drugs available for HCV, no
adequate vaccines or antivirals have been developed for DENV yet despite their similarity. HCV
is responsible for causing a fatal chronic liver disease. This virus is a positive-sense RNA virus of
the Flavivirus family. According to the World Health Organization (WHO), approximately 71
million people are suffering from this disease globally [1]. Some people develop mild symptoms
such as fever and nausea that last for a short period, while some other develop severe symptoms
such abdominal pain and vomiting blood. About 15-30% of those who develop chronic hepatitis
C face a high risk of cirrhosis and liver cancer within 20 years [1]. Many cases of hepatitis C
infection are curable. Most of the treatments currently available for this disease consist of a
combination of antivirals. They are highly dependent upon several factors including the viral strain
and the patient’s condition [2].
Dengue virus (DENV) on the other hand, is a mosquito-borne human pathogen that also
belongs to Flaviviridae. About 2.5 billion people are at risk of infections globally, especially those
that are living in tropical and sub-tropical regions [3]. While most infections are asymptomatic or
cause only mild symptoms, some cases result in severe consequences and deaths. DENV has four
serotypes labelled DENV 1 to 4 that share approximately 65% of their genomes [4]. They can cocirculate with one another and an infection of one serotype can increase the risk of developing
severe symptoms upon a secondary infection of a different serotype. Until now, no adequate
vaccines or antivirals have been developed for this species yet.
Many studies were conducted to compare HCV to DENV since they both belong to the
family of Flaviviridae. Structurally, both viruses possess a positive-strand RNA and are about the
same in size (30-60nm) [5]. Upon cellular infection, they use cellular mechanisms to translate their
RNA into a long polypeptide that is subsequently cleaved into three structural and seven nonstructural proteins. Among the seven non-structural proteins, NS5 of DENV and NS5B of HCV
are the most conserved regions (approximately 70% identical sequence) that serve as a RNAdependent RNA polymerase (RdRp) [5]. Interestingly, NS5 of DENV possesses two functions: a
methyltransferase at the N-terminal and a RdRp at the C-terminal. These functions were found to
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be critical to the viral life cycle since they are responsible for the viral replication. Thus, NS5 and
NS5B are considered as promising enzyme targets for antiviral development. NS3 is another
enzyme that is also very important to the viral replication. NS3 binds to NS2B that is a co-factor
in DENV and to NS4A in HCV [6,7]. Both enzyme complexes possess a trypsin-like serine
protease at the N-terminal domain and a helicase at the C-terminal domain. Disrupting these
enzyme complexes will terminate the viral life cycle. This paper analyzes the NS3 complex of
both HCV and DENV to find similarities and differences between the two enzymes with the aim
to aid in the development of antivirals for DENV. It also investigates the interaction of DENV
NS2B/3 with a potent inhibitor, Aprotinin, through AutoDock.

Figure 1. Illustration of mechanism of action of Hepatitis C Virus (HCV) drugs in hepatocyte (12)

METHODS
In this project, the crystal structures of NS2B/3 and NS5 of both viruses from the Protein Data
Bank were used. Structural analyses of the two viral proteins were done using molecular
visualization system such as PyMOL and RasWin. Since NS2B/3 and NS5 are enzymes with
catalytic activity, a comparison study of their active sites was done with the focus on their catalytic
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triads. ChemDraw, a molecular modeling software, was utilized to construct chemical structures
of several potential inhibitors based on a bovine pancreatic trypsin inhibitor called Aprotinin.
Subsequently, AutoDock that is a molecular simulation software was used to simulate the
interaction between NS2B/3 of DENV and the inhibitors constructed. Binding energies and kI
values of each peptide inhibitor to the protease complex were measured.

RESULTS
I. Structural Analysis
1. Hepatitis C Virus (HCV) NS3/4A Protease
•

PDB ID: 3KEE

•

Name: HCV NS3/4A Protease

•

Class: Hydrolase

•

E.C. Number: 3.4.21.98

HCV NS3/4A is made up of a homodimer protein (NS3) and a polypeptide (NS4A) that is a
cofactor. The crystal structure of this complex obtained is bound to Simeprevir, an inhibitor that
binds competitively to its site of enzymatic activity. This site is located in between the two subdomains of the protein and consists of a catalytic triad. NS3 protein has a total of 631 residues and
contains a trypsin/chymotrypsin-like serine protease in its N-terminal region. However, only about
180 amino acids at this N-terminal are required for a functional serine protease activity. NS4A, on
the other hand, is much shorter in length. It helps stabilize NS3 structure and enhances its
proteolytic activity [2].
NS3 Protein. According to crystal structure obtained from the Protein Data Bank (PDB), the
NS3 protein mRNA encodes for a much larger polyprotein that functions as a protease at the Nterminal and a helicase at its C-terminal [6]. Residues 3-180 of this mRNA encode for 4
polypeptide chains that are identical. Each chain contains 178 amino acids and is folded into two
domains as depicted in Figure 2. Sub-domain 1 contains 69 amino acids (residue 12-80) and is
colored as red. Sub-domain 2 is made up of only 39 amino acids (residue 141-179) and is colored
as yellow. Based on the Structural Classification of Proteins (SCOP) database, each sub-domain
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is a closed β-barrel comprised of 6 β-strands and a greek-key motif [8]. In between these two βbarrels exists a catalytic triad of His57, Asp81 and Ser139 that are very essential to the function of
this protease as shown in Figure 3 [7].

Catalytic Triad

Figure 2. The two β-barrel subdomains of the HCV NS3 protein

Figure 3. The Catalytic Triad of
His57, Asp81 and Ser139 of HCV NS3

NS4A Peptide. NS4A is a short polypeptide that
consists of 19 amino acids, much shorter than NS3
protein. However, its mRNA encodes for a large
polypeptide that subsequently gets cleaved into four
identical NS4A chains. Each chain acts as a cofactor
to help stabilize NS3 protein and activate it. NS4A
does this by inserting its β strand polypeptide into the
N-terminal of the β-barrels of NS3 forming hydrogen
bonds with it [2]. Therefore, NS4A is believed to be
mandatory for the proper folding of the NS3
Figure 4. NS4A peptide
highlighted in magenta

protease.
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2. Dengue Virus (DENV) NS2B/NS3 Protease
•

PDB ID: 2FOM

•

Name: Dengue Virus NS2B/NS3 Protease

•

Class: Hydrolase

•

E.C. Number: 3.4.21.98

This enzyme complex is made up of a non-structural protein (NS3) and a polypeptide (NS2B)
that is a cofactor. The active site of this enzyme-complex comprises of a catalytic triad that is
located in between the two sub-domains of the complex due its proteolytic activity. NS3 protein
has a dual functions: it has a trypsin/chymotrypsin-like serine protease at its N-terminal and a
helicase at the C-terminal [7]. Only 185 amino acids at the N-terminal are required for a functional
serine protease activity. NS2B, on the other hand, is much shorter in length. It helps stabilize NS3
structure and enhances its proteolytic activity [2].
Catalytic Triad

Figure 5. The Catalytic Triad of
His51, Asp75 and Ser135 DENV NS3

Figure 4. The two β-barrel subdomains of the DENV NS3 protein

NS3 Protein. According to the Protein Data Bank (PDB), NS3 polypeptide is folded into two
domains as depicted in Figure 4 [7]. Sub-domain 1 contains 60 amino acids (residue 21-80) and is
colored as yellow above. Sub-domain 2 is made up of only 72 amino acids (residue 95-166) and
is colored as green. Based on the Structural Classification of Proteins (SCOP) database, each subdomain is a closed β-barrel comprised of 6 β-strands and a greek-key motif [8]. In between these
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two β-barrels exists a catalytic triad of His51, Asp75 and Ser135 that are very essential to the function
of this protease as shown in Figure 5.
NS2B Peptide. NS2B is a short polypeptide that
consists of 62 amino acids, much shorter than NS3
protein. This non-structural protein acts as a cofactor
to help stabilize NS3 protein. According to Zuo et
al., NS2B also facilitates binding of substrates and
promotes catalytic acitivity. It does this by
estabilishing a great number of hydrogen bonds and
hydrophobic interactions with NS3. Therefore,
NS2B is believed to be mandatory for the proper
folding of the NS3 protease. Furthermore, it was also
Figure 6. NS2B peptide highlighted in
red inserted through the two domains of
NS3 protein colored in magenta

shown that the binding of NS2B to NS3 added five
more potential binding sites to the complex that were
not present in NS3 protease by itself.

II. AutoDock

Aprotinin, also known as bovine pancreatic
trypsin inhibitor (BPTI), is a protein that is used
commonly used to reduce bleeding during complex
surgery [9]. Interestingly, it was also found to be a
strong inhibitor to NS2B/3 of DENV according to
Noble and colleauges [7]. Thus, Aprotinin’s
interaction with the protease complex of DENV was
studied using AutoDock. Noble’s work suggests that
Aprotinin binds competitively to the protease’s
active site in between its two domains [7]. This site
Figure 7. Overview of the DENV-3
protease (NS3, purple; NS2B, orange)
bound to aprotinin (yellow) shown in
cartoon representation from the Protein
Data Bank (ID:3U1J)

also involves the catalytic triad of His51, Asp75 and
Ser135. Based on this crystal structure, residues 13-
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19 appear to interact with the protease complex the most. Thus, this region of Aprotinin was
truncated from Cys14 to Ile19 as shown in Figure 8.

Figure 8. Residue Pro13, Cys14, Lys15, Ala16, Arg17, Ile18 and Ile19 of Aprotinin

The tail of this peptoid was modified to have three different functional groups: amide, aldehyde
and carboxylic acid. Each structure was docked onto the active site of DENV’s NS2B/3 and the
results are summarized in Table 1.

Table 1. Binding energy and dissociation constant of the three peptoids docked onto NS2B/3
Functional Group

Binding Energy

Dissociation Constant (Ki)

Amide

-3.99 kCal/mol

1.19mM

Aldehyde

-3.38 kCal/mol

3.31mM

Carboxylic acid

-3.82 kCal/mol

1.58mM

Figure 9. Residue 13-19 of Aprotinin with an amide tail docked onto DENV NS2B/3 protease shown in
space-filling model (left) and ribbon (right)
9

Figure 10. Residue 13-19 of Aprotinin with an aldehyde tail (green) and a carboxylic acid
tail (pink) docked onto DENV NS2B/3 protease shown in space-filling model

As expected, the three peptoids all bind to the binding site of the protease. The peptoid bearing
an aldehyde tail (Figure 9) was observed to spread on the surface of the NS2B/3 having all its
residues interact with the protease. Cysteine was the only residue of this peptoide that was observed
to point out of the protein and to not interact with it. The binindg energy of this peptoid was
calculated by AutoDock to be -3.99, the highest value of all three peptoids, which is equivalent to
about 1.19mM of kI.
On the other hand, the peptoid bearing an aldehyde tail (Green) and the peptoid bearing a
carboxylic acid tail (Pink) in Figure 10 were observed to spread on the surface of the protease in a
much smaller region. Not all of their residues interact with the binding site of the enzyme complex.
Key residues that participate in the interaction include Proline, Lysine, Arginine and one of the
Isoleucine residues in both peptoids bearing an aldhehyde tail and a carboxylic acid tail. The
binding energy of these interactions were calculated to be -3.38 and -3.82 for the aldehyde and
carboxylic acid peptoide respectively. Interestingly, the dissociation constant of adehye was found
to be 3.31mM, twice as much as that of carboxylic acid at 1.58mM.

DISCUSSION
From a rough comparison, not many differences can be observed from the two enzyme
complexes. Both NS3 proteins require a co-factor for their proper conformation and activation of
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the binding sites. Moreover, both binding sites are relatively conserved and are comprised of a
catalytic triad of His, Asp and Ser [6,7]. However, Aguilera-Pesantes et al. suggested that
NS2B/NS3 of DENV has an altered specificity and can recognize only sites that contain two
cationic residues [10]. This does not seem to be the case for NS3/NS4A of HCV at all. This
characteristic is believed to be very important for antiviral development against DENV.
Based on results obtained from AutoDock simulation, cysteine residue did not participate in
any interaction with the NS2B/3 protease in all three peptoids. This is consistent to expectation
since this residue is responsible for forming one of the three cystine bridges in Aprotinin that are
crucial to its tertiary structure. Furthermore, as has been discussed earlier, the active site of NS2B/3
protease of DENV interacts favorably with dibasic compounds [10]. All three peptoids in this
study contain an arginine and a lysine residue in their structure. Their AutoDock results showed
that these two residues interact extensively with the binding site of the protease in different
conformations although they were not observed to interact with any residues of the catalytic triads.
Additionally, the binding energies of the three peptides were much higher than expected. The
Ki value of Aprotinin for NS2B/3 was reported to be 0.0026µM [7]. Thus, the values obtained
were 6 folds larger than reported. While a good inhibitor usually have a Ki value in the milimolar
concentration, the resulted values were still 3 folds higher. This is thought to be accountable for
by the absence of the structure rigidity. As suggested by Lin et al., a good inhibitor of DENV
NS2B/3 should have a rigid structure due to the flat surface of its binding site [11].
Overall, the binding loop of Aprotinin has been shown to bind to the active site of NS2B/3 of
DENV. The three peptoids derived from this loop were 7 amino acids in length and were modified
to have an amide tail, an aldehyd tail and a carboxylic acid tail. All peptoids bound to the active
site of the enzyme complex near the catalytic triad although the interactions were not as strong as
those in Aprotinin itself. Nonetheless, they demonstrate a good potential to for targeting the
NS2B/3 protease. Further optimizations include increasing the rigidity of the structure through
cyclization and eliminating residues that do not participate in the interaciton with the enzyme.
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